Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.64 |
| ▸ | PYGL | P06737 | 10/20 | 0.61 |
| ▸ | PYGM | P11217 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274133 | 0.96 | MEN1 (0.64) | MEN1KMT2AFFAR1PYGLPYGM | |
| SCHEMBL2271374 | 0.91 | PYGL (0.67) | MEN1KMT2AFFAR1PYGLPYGM | |
| SCHEMBL2272594 | 0.90 | PYGL (0.72) | MEN1KMT2AFFAR1PYGLPYGM | |
| SCHEMBL2271588 | 0.87 | SERPINE1 (0.64) | MEN1KMT2APYGLPYGMNPC1 | |
| SCHEMBL2270545 | 0.86 | FFAR1 (0.56) | MEN1KMT2AFFAR1PYGLPYGM | |
| SCHEMBL27716645 | 0.85 | FFAR1 (0.55) | MEN1KMT2AFFAR1PYGLPYGM | |
| SCHEMBL2276538 | 0.84 | CD40 (0.65) | MEN1KMT2AERO1ANPC1MITF | |
| SCHEMBL2274898 | 0.84 | SERPINE1 (0.60) | MEN1KMT2APYGLPYGMNPC1 | |
| SCHEMBL2274811 | 0.83 | PYGM (0.57) | MEN1KMT2APYGLPYGMPOLB | |
| SCHEMBL2273044 | 0.83 | CYP2C9 (0.61) | MEN1KMT2APYGLPYGMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | MEN1 3105/4885KMT2A 1669/4885FFAR1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.